Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 60%
Sell 20%
Strong Sell 0%

Bulls say

Sutro Biopharma's positive outlook is underpinned by a recent valuation increase of its product STRO-004, which rose to $50 million from $25 million, reflecting strong preclinical data and anticipation of an Investigational New Drug (IND) filing later this year. Additionally, the company has demonstrated significant improvements in patient outcomes with Tivdak, which has shown enhanced overall survival (OS) and progression-free survival (PFS) metrics, as well as a notable increase in the overall response rate (ORR) compared to traditional chemotherapy. Lastly, the accelerated approval of Tivdak in 2021 for metastatic cervical cancer, with full approval anticipated in 2024, further substantiates the company's growth potential and market position within the biopharmaceutical sector.

Bears say

Sutro Biopharma faces potential challenges in its development of biopharmaceutical products due to the limitations associated with antibodies that bind preferentially to specific conformations, which may hinder effective and uniform tumor targeting. This suboptimal binding could adversely impact the downstream performance of antibody-drug conjugates (ADCs), including critical factors such as internalization, payload delivery, and overall efficacy. Additionally, the reported off-tissue toxicities linked to TF-targeting mechanisms raise concerns regarding the safety profile of the company's products, which could further complicate their commercial viability.

STRO has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Hold based on their latest research and market trends.

According to 5 analysts, STRO has a Hold consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.